Adage Capital Partners’s Terns Pharmaceuticals TERN Stock Holding History

Adage Capital Partners’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$112M	Sell	2,124,817 -3,425,183	-62%	-$141M	0.17%	118
2025 Q4	$224M	Buy	5,550,000 +1,611,000	+41%	+$37.2M	0.34%	47
2025 Q3	$29.6M	Buy	3,939,000 +2,659,000	+208%	+$17M	0.05%	365
2025 Q2	$4.77M	Buy	+1,280,000	New	+$4M	0.01%	708
2024 Q3	–	Sell	-975,000	Closed	-$6.64M	–	936
2024 Q2	$6.64M	Buy	975,000 +125,000	+15%	+$757K	0.01%	673
2024 Q1	$5.58M	Sell	850,000 -200,000	-19%	-$1.31M	0.01%	685
2023 Q4	$6.81M	Buy	1,050,000 +950,000	+950%	+$5.02M	0.01%	653
2023 Q3	$503K	Sell	100,000 -50,000	-33%	-$317K	﹤0.01%	781
2023 Q2	$1.31M	Buy	+150,000	New	+$1.75M	﹤0.01%	759

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Adage Capital Partners's TERN Position: Q1 2026 in Review

Adage Capital Partners reduced its Terns Pharmaceuticals (TERN) stake by 62% in Q1 2026, selling an estimated $141M and leaving 2,124,817 shares worth $112M. The position accounts for 0.17% of the portfolio, ranked #118.

Adage Capital Partners first reported a position in TERN in Q2 2023 and has held it in 9 quarters since. The position peaked at $224M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Adage Capital Partners held 2,124,817 shares of Terns Pharmaceuticals worth $112M as of Q1 2026.
Adage Capital Partners sold 3,425,183 Terns Pharmaceuticals shares in Q1 2026, an estimated $141M.
Terns Pharmaceuticals made up 0.17% of Adage Capital Partners's portfolio in Q1 2026, its #118 holding.
Adage Capital Partners first reported a position in Terns Pharmaceuticals in Q2 2023 and has held it in 9 quarters since.
Adage Capital Partners's Terns Pharmaceuticals position peaked at $224M in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.